Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cetuximab beta - Sinomab/Sorrento

Next Previous
Drug Profile

Cetuximab beta - Sinomab/Sorrento

Alternative Names: cetuximab beta; Cetuximab biobetter - Sinomab/Sorrento; Cetuximab biosimilar/biobetter - Sinomab/Sorrento; CMAB 009; Enlituo; STI-001

Latest Information Update: 02 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mabtech
  • Developer Shanghai Biomabs Pharmaceuticals; Shanghai Zhangjiang Biotechnology; Sinomab
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; ErbB receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer

Most Recent Events

  • 30 Aug 2026 Taizhou Mabtech Pharmaceutical plans a phase II/III trial for Squamous cell cancer (Late stage disease, Metastatic disease, Recurrent, First line therapy, Combination therapy) in China (IV) (NCT07791745)
  • 19 May 2026 Taizhou Mabtech Pharmaceutical plans a phase III trial for Colorectal Cancer (First-line therapy, Combination therapy, Late-stage disease, Metastatic disease) in China, in June 2026 (IV, Infusion) (NCT07595276)
  • 11 Nov 2025 Taizhou Mabtech Pharmaceutical plans a phase I trial for Healthy volunteers in China (IV) (NCT07246291)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top